MONTREAL, QC, Canada – September 15 th, 2015

Laurent Pharmaceuticals Inc. announced today that the LAU-7b program addressing aberrant inflammation is featured in the September 14th issue of BioCentury, one of the most widely read publications in the pharma industry. 

Published under the title “Balancing Act”, the article describes how Laurent Pharmaceuticals thinks its LAU-7b can carve out a niche in CF by correcting the inflammatory imbalance in CF patients and reduce lung deterioration over time, when given on top of standard of care.

Read the article


Laurent Pharmaceuticals to participate at the Biotech Showcase January 9-11th 2017, San Francisco, CA, USA

Laurent Pharmaceuticals to participate at the North American Cystic Fibrosis Conference, October 27th-29th 2016, Orlando, FL